Evidence map›Paper›PMID 24833648›Full record

Trial reportCirculation. Heart failure2014

Resting ventricular-vascular function and exercise capacity in heart failure with preserved ejection fraction: a RELAX trial ancillary study.

Selma F Mohammed, Barry A Borlaug, Steven McNulty, Gregory D Lewis, Grace Lin, Rosita Zakeri, Marc J Semigran, Martin LeWinter, Adrian F Hernandez, Eugene Braunwald and 1 more

Registry-linked trialOpen access · bronzeAbstract readMulticenter StudyRandomized Controlled Trial
In one paragraph

Trial report in Circulation. Heart failure, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT00763867 (Phosphodiesterase-5 Inhibition to Improve Clinical Status and Exercise Capacity in Diastolic Heart Failure), which is not on this map. Cited by 23 papers.

0numbers the graph read from it
0cells of the map it votes in
23citing papers in PubMed
3.7field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT00763867 phase3completednot on this map

Phosphodiesterase-5 Inhibition to Improve Clinical Status and Exercise Capacity in Diastolic Heart Failure (RELAX)

TypeinterventionalSponsorDuke UniversityRan2008 to 2012Enrolled216ConditionsHeart FailureArmsPlacebo, Sildenafil
3 · Its place in the literature

Who cites it

23 citing papers in PubMed, 46 citations in OpenAlex.

  1. Trial
  2. Trial
  3. Trial
  4. Trial
  5. Review
  6. Review
  7. Article
  8. Article
  9. Article
  10. Review
  11. Article
  12. Review
  13. Application of Guideline-Based Echocardiographic Assessment of Left Atrial Pressure to Heart Failure with Preserved Ejection Fraction.Journal of the American Society of Echocardiography : official publication of the American Society of Echocardiography · 2021
    Article
  14. Review
  15. Article
  16. Article
  17. Article
  18. Article
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 3 institutions in 1 country.

Selma F MohammedFrom the Division of Cardiovascular Diseases (S.F.M., B.A.B., G.L., R.Z., M.M.R.) and Mayo Graduate School (S.F.M., R.Z.), Mayo Clinic, Rochester, MN; Duke Clinical Research Institute, Durham, NC (S.M., A.F.H.); Massachusetts General Hospital, Boston, MA (G.D.L., M.J.S.); University of Vermont, Burlington, VT (M.L.); and Harvard Medical School, Boston, MA (E.B.). mohammed.selma@mayo.edu.
Barry A BorlaugFrom the Division of Cardiovascular Diseases (S.F.M., B.A.B., G.L., R.Z., M.M.R.) and Mayo Graduate School (S.F.M., R.Z.), Mayo Clinic, Rochester, MN; Duke Clinical Research Institute, Durham, NC (S.M., A.F.H.); Massachusetts General Hospital, Boston, MA (G.D.L., M.J.S.); University of Vermont, Burlington, VT (M.L.); and Harvard Medical School, Boston, MA (E.B.).
Steven McNultyFrom the Division of Cardiovascular Diseases (S.F.M., B.A.B., G.L., R.Z., M.M.R.) and Mayo Graduate School (S.F.M., R.Z.), Mayo Clinic, Rochester, MN; Duke Clinical Research Institute, Durham, NC (S.M., A.F.H.); Massachusetts General Hospital, Boston, MA (G.D.L., M.J.S.); University of Vermont, Burlington, VT (M.L.); and Harvard Medical School, Boston, MA (E.B.).
Gregory D LewisFrom the Division of Cardiovascular Diseases (S.F.M., B.A.B., G.L., R.Z., M.M.R.) and Mayo Graduate School (S.F.M., R.Z.), Mayo Clinic, Rochester, MN; Duke Clinical Research Institute, Durham, NC (S.M., A.F.H.); Massachusetts General Hospital, Boston, MA (G.D.L., M.J.S.); University of Vermont, Burlington, VT (M.L.); and Harvard Medical School, Boston, MA (E.B.).
Grace LinFrom the Division of Cardiovascular Diseases (S.F.M., B.A.B., G.L., R.Z., M.M.R.) and Mayo Graduate School (S.F.M., R.Z.), Mayo Clinic, Rochester, MN; Duke Clinical Research Institute, Durham, NC (S.M., A.F.H.); Massachusetts General Hospital, Boston, MA (G.D.L., M.J.S.); University of Vermont, Burlington, VT (M.L.); and Harvard Medical School, Boston, MA (E.B.).
Rosita ZakeriFrom the Division of Cardiovascular Diseases (S.F.M., B.A.B., G.L., R.Z., M.M.R.) and Mayo Graduate School (S.F.M., R.Z.), Mayo Clinic, Rochester, MN; Duke Clinical Research Institute, Durham, NC (S.M., A.F.H.); Massachusetts General Hospital, Boston, MA (G.D.L., M.J.S.); University of Vermont, Burlington, VT (M.L.); and Harvard Medical School, Boston, MA (E.B.).
Marc J SemigranFrom the Division of Cardiovascular Diseases (S.F.M., B.A.B., G.L., R.Z., M.M.R.) and Mayo Graduate School (S.F.M., R.Z.), Mayo Clinic, Rochester, MN; Duke Clinical Research Institute, Durham, NC (S.M., A.F.H.); Massachusetts General Hospital, Boston, MA (G.D.L., M.J.S.); University of Vermont, Burlington, VT (M.L.); and Harvard Medical School, Boston, MA (E.B.).
Martin LeWinterFrom the Division of Cardiovascular Diseases (S.F.M., B.A.B., G.L., R.Z., M.M.R.) and Mayo Graduate School (S.F.M., R.Z.), Mayo Clinic, Rochester, MN; Duke Clinical Research Institute, Durham, NC (S.M., A.F.H.); Massachusetts General Hospital, Boston, MA (G.D.L., M.J.S.); University of Vermont, Burlington, VT (M.L.); and Harvard Medical School, Boston, MA (E.B.).
Adrian F HernandezFrom the Division of Cardiovascular Diseases (S.F.M., B.A.B., G.L., R.Z., M.M.R.) and Mayo Graduate School (S.F.M., R.Z.), Mayo Clinic, Rochester, MN; Duke Clinical Research Institute, Durham, NC (S.M., A.F.H.); Massachusetts General Hospital, Boston, MA (G.D.L., M.J.S.); University of Vermont, Burlington, VT (M.L.); and Harvard Medical School, Boston, MA (E.B.).
Eugene BraunwaldFrom the Division of Cardiovascular Diseases (S.F.M., B.A.B., G.L., R.Z., M.M.R.) and Mayo Graduate School (S.F.M., R.Z.), Mayo Clinic, Rochester, MN; Duke Clinical Research Institute, Durham, NC (S.M., A.F.H.); Massachusetts General Hospital, Boston, MA (G.D.L., M.J.S.); University of Vermont, Burlington, VT (M.L.); and Harvard Medical School, Boston, MA (E.B.).
Margaret M RedfieldFrom the Division of Cardiovascular Diseases (S.F.M., B.A.B., G.L., R.Z., M.M.R.) and Mayo Graduate School (S.F.M., R.Z.), Mayo Clinic, Rochester, MN; Duke Clinical Research Institute, Durham, NC (S.M., A.F.H.); Massachusetts General Hospital, Boston, MA (G.D.L., M.J.S.); University of Vermont, Burlington, VT (M.L.); and Harvard Medical School, Boston, MA (E.B.).
Clinical Research Institute · USUniversity of Vermont · USHarvard University · US

Funding

MAYO CLINIC CENTER FOR TRANSLATIONAL SCIENCE ACTIVITIESUL1RR024150 · NCRR · MAYO CLINIC ROCHESTER · PI RIZZA, ROBERT A. · 2006 to 2011
$66.4M
Mayo Clinic Center for Translational Science ActivitiesUL1TR000135 · NCATS · MAYO CLINIC ROCHESTER · PI KHOSLA, SUNDEEP · 2012 to 2015
$41.2M
Heart Failure Clinical Research Network Coordinating CenterU10HL084904 · NHLBI · DUKE UNIVERSITY · PI ANSTROM, KEVIN J, HERNANDEZ, ADRIAN · 2012 to 2018
$38.0M
Recruitment and Phenotyping CoreP01HL076611 · NHLBI · MAYO CLINIC ROCHESTER · PI BURNETT, JOHN C · 2005 to 2015
$19.6M
CARDIOVASOLOGYT32HL007111 · NHLBI · MAYO CLINIC ROCHESTER · PI Barry A. Borlaug · 1985 to 2026
$8.7M
Mayo Heart Failure Regional Clinical CenterU10HL110262 · NHLBI · MAYO CLINIC ROCHESTER · PI REDFIELD, MARGARET M · 2012 to 2018
$3.6M
Harvard Regional Clinical Center of the NHLBI Heart Failure NetworkU10HL110337 · NHLBI · MASSACHUSETTS GENERAL HOSPITAL · PI GIVERTZ, MICHAEL M, LEWIS, GREGORY DYER · 2012 to 2018
$3.5M
Mayo Heart Failure Regional Clinical CenterU01HL084907 · NHLBI · MAYO CLINIC ROCHESTER · PI REDFIELD, MARGARET M · 2006 to 2011
$2.4M
Treatment of Diastolic Heart Failure via AAV-9 Mediated Gene TransferR01HL105418 · NHLBI · MAYO CLINIC ROCHESTER · PI REDFIELD, MARGARET M · 2012 to 2015
$1.5M
NCATS NIH HHS UL1 TR000135NCRR NIH HHS UL1 RR024150NCRR NIH HHS UL1RR024150NHLBI NIH HHS P01 HL076611NHLBI NIH HHS P01HL 076611NHLBI NIH HHS R01 HL105418NHLBI NIH HHS T32 HL007111NHLBI NIH HHS T32-HL007111NHLBI NIH HHS U01 HL084907NHLBI NIH HHS U10 HL084904NHLBI NIH HHS U10HL084904NHLBI NIH HHS U10HL084907NHLBI NIH HHS U10 HL110262NHLBI NIH HHS U10 HL110337
6 · The paper itself

Abstract

backgroundExercise intolerance is a hallmark of heart failure, but factors associated with impaired exercise capacity in heart failure with preserved ejection fraction are unclear. We hypothesized that in heart failure with preserved ejection fraction, the severity of resting ventricular and vascular dysfunction are associated with impairment in exercise tolerance as assessed by peak oxygen consumption. METHODS AND

resultsSubjects with heart failure with preserved ejection fraction enrolled in the PhosphodiesteRasE-5 Inhibition to Improve CLinical Status And EXercise Capacity in Diastolic Heart Failure (RELAX) clinical trial (n=216) underwent baseline Doppler echocardiography, cardiopulmonary exercise testing, and cardiac MRI. RELAX participants were elderly (median age 69 years) and 48% were women. Ejection fraction (60%) and stroke volume (77 mL) were normal, while diastolic dysfunction (medial E/e', 16; deceleration time, 185 ms; left atrial volume, 44 mL/m(2)) and increased arterial load (arterial elastance, 1.51 mm Hg/mL) were evident. Peak oxygen consumption was reduced (11.7 mLkg(-1)min(-1), 1141 mL/min) and age, sex, body mass index, hemoglobin, and chronotropic response collectively explained 64% of the variance in raw peak oxygen consumption (mL/min). After adjustment for these variables, left ventricular structure (diastolic dimension [1.5%, P=0.008] and left ventricular mass [1.6%, P=0.008]), resting stroke volume (2.0%, P=0.002), left ventricular diastolic dysfunction (deceleration time [0.9%, P=0.03] and E/e' [1.4%, P=0.009]), and arterial function (arterial elastance [2.1%, P=0.002] and systemic arterial compliance [1.5%, P=0.007]), each explained only a small additional portion of the variance in peak oxygen consumption.

conclusionsIn heart failure with preserved ejection fraction, potentially modifiable factors (obesity, anemia, and chronotropic incompetence) are strongly associated with exercise capacity, whereas resting measures of ventricular and vascular structure and function are not. CLINICAL TRIAL REGISTRATION URL: http://www.clinicaltrials.gov. Unique identifier: NCT00763867.

Indexed as

Ancillary Services, HospitalAgedDiastoleEchocardiography, DopplerExercise TestExercise ToleranceFemaleFollow-Up StudiesHeart FailureHumansMagnetic Resonance Imaging, CineMaleMiddle AgedOutpatientsOxygen ConsumptionRestdiastoleexerciseheart failureoxygen consumption

Identifiers

PMID24833648
PMCPMC4119596
OpenAlexW2050585111

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.